{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:38:54Z","timestamp":1790678334449,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.2146\/ajhp160798","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T10:40:09Z","timestamp":1500979209000},"page":"1135-1141","source":"Crossref","is-referenced-by-count":20,"title":["Selexipag for the treatment of pulmonary arterial hypertension"],"prefix":"10.1093","volume":"74","author":[{"given":"Zachary R.","family":"Noel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Kido","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, South Dakota State University, Sioux Falls, SD, and Department of Pharmacy, Avera McKennan Hospital, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy E.","family":"Macaulay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, and UKHealthCare Jack and Linda Gill Heart Institute, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103311567500_b1-0741135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J."},{"key":"key\n\t\t\t\t2019041103311567500_b2-0741135","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/CIRCULATIONAHA.108.847707","article-title":"Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies","volume":"121","author":"Archer","year":"2010","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041103311567500_b3-0741135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","article-title":"Pulmonary arterial hypertension","volume":"8","author":"Montani","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"key\n\t\t\t\t2019041103311567500_b4-0741135","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041103311567500_b5-0741135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","article-title":"Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report","volume":"146","author":"Taichman","year":"2014","journal-title":"Chest."},{"key":"key\n\t\t\t\t2019041103311567500_b6-0741135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J."},{"key":"key\n\t\t\t\t2019041103311567500_b7-0741135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0897190015615902","article-title":"An update on the management of pulmonary arterial hypertension and the pharmacist\u2019s role","volume":"29","author":"Macaulay","year":"2016","journal-title":"J Pharm Pract."},{"key":"key\n\t\t\t\t2019041103311567500_b8-0741135","volume-title":"Ventavis (iloprost) package insert","year":"2016"},{"key":"key\n\t\t\t\t2019041103311567500_b9-0741135","volume-title":"Uptravi (selexipag) prescribing information","year":"2015"},{"key":"key\n\t\t\t\t2019041103311567500_b10-0741135","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b11-0741135","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041103311567500_b12-0741135","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","article-title":"A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery","volume":"326","author":"Kuwano","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b13-0741135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.110.169748","article-title":"Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function","volume":"335","author":"Morrison","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b14-0741135","doi-asserted-by":"crossref","first-page":"788","DOI":"10.5414\/CP202318","article-title":"Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study","volume":"53","author":"Baldoni","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b15-0741135","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bcp.12650","article-title":"Effect of lopinavir\/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects","volume":"80","author":"Kaufmann","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"key\n\t\t\t\t2019041103311567500_b16-0741135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40256-015-0117-4","article-title":"Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag","volume":"15","author":"Kaufmann","year":"2015","journal-title":"Am J Cardiovasc Drugs."},{"key":"key\n\t\t\t\t2019041103311567500_b17-0741135","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.clinthera.2016.03.014","article-title":"Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects","volume":"38","author":"Bruderer","year":"2016","journal-title":"Clin Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b18-0741135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bcp.12963","article-title":"Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment","volume":"82","author":"Kaufmann","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"key\n\t\t\t\t2019041103311567500_b19-0741135","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J."},{"key":"key\n\t\t\t\t2019041103311567500_b20-0741135","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041103311567500_b21-0741135","unstructured":"ClincalTrials.gov. Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01112306?term=griphon&rank=2 (accessed 2016 Dec 20)."},{"key":"key\n\t\t\t\t2019041103311567500_b22-0741135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DDDT.S75565","article-title":"A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist","volume":"9","author":"Hoch","year":"2014","journal-title":"Drug Des Devel Ther."},{"key":"key\n\t\t\t\t2019041103311567500_b23-0741135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000367630","article-title":"Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects","volume":"94","author":"Bruderer","year":"2014","journal-title":"Pharmacology."},{"key":"key\n\t\t\t\t2019041103311567500_b24-0741135","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041103311567500_b25-0741135","unstructured":"ClinicalTrials.gov. The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558231 (accessed 2016 Dec 20)."},{"key":"key\n\t\t\t\t2019041103311567500_b26-0741135","volume-title":"Redbook Online [online database]"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/15\/1135\/28336342\/ajhp1135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T15:19:37Z","timestamp":1569943177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/15\/1135\/5102810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160798","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,8,1]]}}}